Zybrestat selectively targets and collapses tumor vasculature, thereby depriving the tumor of oxygen and causing death of tumor cells.
Falcon is a randomized, controlled Phase 2 study investigating the addition of Zybrestat to standard therapy (carboplatin, paclitaxel, and bevacizumab, or C/P/Bev) in patients with Stage IIIb or IV predominantly non-squamous NSCLC.
The data demonstrated that the combination regimen of Zybrestat plus bevacizumab, carboplatin and paclitaxel (Zybrestat arm) was well-tolerated when compared with the control arm of the study (standard chemotherapy plus bevacizumab).
Moreover, patients with tumor burden greater than 10 cm showed improvements in overall survival for patients receiving Zybrestat in addition to bevacizumab and chemotherapy.